CROs Rise to COVID Pandemic Challenges
Industry must take advantage of "lessons learned."
Several years ago, the Board of Directors of the Association of Clinical Research Organizations (ACRO) decided to expand the boundaries of membership to welcome not only CROs but technology companies as well. This recognition that the software and platforms provided by technology companies are increasingly integral to the design, execution, and analysis of clinical trials reinforced the association’s long commitment to innovation in clinical development, and today ACRO’s membership is roughly half CROs and half technology companies. The mission of ACRO—to advocate for a positive and consistent regulatory and business environment in which companies that perform a wide range of clinical development activities can operate worldwide—did not change. But our voice became larger and more diverse.
In supporting clinical development projects from beginning to end, CROs and technology providers have a unique vantage point, interacting with all the stakeholders in the enterprise: sponsors, investigators, institutional review boards (IRBs) and ethics committees, research sites, research participants, and regulators.
This unique perspective on the research environment affords opportunities for data collection, and in 2020 and 2021 ACRO undertook landscape
We think that is an important contribution that ACRO can make, and aim to continue yearly assessments of RBQM and DCTs and other emerging approaches to improving the conduct of clinical trials.
Beyond gathering data to characterize the current landscape, CROs and technology companies invest heavily in innovation and thought leadership, and ACRO harnesses collaboration across member companies to produce knowledge and tools that can benefit all stakeholders. For example, our DCT
Another topic on which the CROs and technology companies will lead in the future is the use of real-world data/real-world evidence (RWD/RWE), which will not only provide more fulsome data for drug development, but ultimately could help to begin bridging the gap between clinical research and clinical care.
The COVID-19 pandemic very much highlighted the need for our entire industry to improve diversity and inclusion (D&I) in clinical research, and ACRO member companies are addressing D&I issues on every level, from patient and workforce recruitment to engaging with regulators and legislators on the development of policies that will support and incentivize a fairer and more equitable research environment.
COVID also proved the enormous adaptability and resilience of all the stakeholders in the clinical research enterprise; overall, CROs and technology companies, sponsors, sites, patients, IRBs, and regulators rose to meet the extraordinary challenges of a worldwide pandemic. ACRO and its member companies are determined to take advantage of the “lessons learned” over the last two years—and we look forward to a bright future for drug development.
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
- Why Decentralized Trials Face Slow Adoption Despite Strong Data
August 26th 2025